Integra LifeSciences
English:US
Integra LifeSciences
Investor Home
Press Releases
Events & Presentations
Corporate Governance
Financial Information
Stock Information
Contact Us


 
Committee Composition
Chairman of the Board = Chairman of the Board Committee Chair = Chair Committee Member = Member Independent Director = Independent Under NASDAQ Listing Standards
  Audit Nominating and Corporate Governance Compensation
Stuart M. Essig Ph.D Chairman of the Board      
Peter J. Arduini      
Keith Bradley Ph.D. Independent Director   Member of Nominating and Corporate Governance Committee Committee Chair for Compensation Committee
Richard E. Caruso Ph.D. Independent Director      
Lloyd W. Howell Jr.      
Neal Moszkowski Independent Director   Member of Nominating and Corporate Governance Committee Member of Compensation Committee
Raymond G. Murphy Independent Director Committee Chair for Audit Committee    
Christian S. Schade Independent Director Member of Audit Committee   Member of Compensation Committee
James M. Sullivan Independent Director Member of Audit Committee Committee Chair for Nominating and Corporate Governance Committee  
Anne M. VanLent Independent Director Member of Audit Committee    
Anne M. VanLent
President, AMV Advisors

ANNE M. VANLENT has been a director of the Company since 2004. She is currently President of AMV Advisors, providing corporate strategy and financial consulting services to emerging growth life sciences companies. Ms. VanLent had been Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc., a publicly-traded pharmaceutical company that develops and markets prescription dermatology products, from May 2002 through April 2008. From July 1997 to October 2001, she was the Executive Vice President — Portfolio Management for Sarnoff Corporation, a multidisciplinary research and development firm. From 1985 to 1993, she served as Senior Vice President and Chief Financial Officer of The Liposome Company, Inc., a publicly-traded biopharmaceutical company. Ms. VanLent also currently serves as a director and chair of the audit committee for Tranzyme Pharma, Inc., a NASDAQ-listed company. She was a director and chair of the audit committee of Penwest Pharmaceuticals Co., also a NASDAQ-listed company, until its sale to Endo Pharmaceuticals in the fall of 2010. Ms. VanLent received a B.A. degree in Physics from Mount Holyoke College.